Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.2K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.1K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.1K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

448
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
448
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

240
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
240
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

239
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
239
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

267
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
267

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The landscape of serum autoantibodies in lupus nephritis.

Autoimmunity reviews·2026
Same author

The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology.

Journal of translational autoimmunity·2026
Same author

Advancing Care in Lupus Nephritis: Expert Perspectives on Current Practices and Future Directions in Italy.

Journal of clinical medicine·2026
Same author

Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology.

RMD open·2026
Same author

The landscape of artificial intelligence in carbon ion radiotherapy: A scoping review.

Tumori·2026
Same author

Correction to: IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler Registry.

Clinical and experimental rheumatology·2026

Related Experiment Video

Updated: Jan 9, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.5K

Giant cell arteritis in clinical practice: beyond GiACTA.

Francesca Regola1, Jacopo Mora2, Matteo Riva3

  • 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili di Brescia; and Department of Clinical and Experimental Sciences, University of Brescia, Italy. f.regola@unibs.it.

Clinical and Experimental Rheumatology
|December 2, 2025
PubMed
Summary
This summary is machine-generated.

Giant cell arteritis (GCA) treatment with tocilizumab (TCZ) reduces glucocorticoid (GC) dependence and side effects compared to GCs alone or with methotrexate (MTX). TCZ offers a steroid-sparing effect and clinical efficacy in GCA patients.

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.3K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.0K

Related Experiment Videos

Last Updated: Jan 9, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.5K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.3K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.0K

Area of Science:

  • Rheumatology and Immunology
  • Clinical Pharmacology
  • Vasculitis Research

Background:

  • Giant cell arteritis (GCA) treatment commonly involves high-dose glucocorticoids (GCs).
  • GCs are linked to significant side effects and disease relapses.
  • Steroid-sparing agents are crucial for managing GCA effectively.

Purpose of the Study:

  • To analyze glucocorticoid (GC) side effects in a real-world GCA cohort.
  • To assess the steroid-sparing efficacy of tocilizumab (TCZ) and methotrexate (MTX).
  • To evaluate GC toxicity using the Glucocorticoid Toxicity Index (GTI) v2.0.

Main Methods:

  • Retrospective cohort study of 150 newly diagnosed GCA patients.
  • Patients classified into three groups: GCs alone, GCs plus MTX, and GCs plus TCZ.
  • Glucocorticoid Toxicity Index (GTI) calculated over a 5-year follow-up.

Main Results:

  • 88% of patients experienced GC side effects; cumulative GC dose predicted worsening damage.
  • TCZ significantly reduced GC dose by 25%, leading to fewer side effects (65% vs. 90%) and no relapses (0% vs. 38%).
  • TCZ provided independent protection against relapses; MTX showed no comparable benefits.

Conclusions:

  • Cumulative GC dose in GCA therapy correlates with induced damage, as measured by GTI.
  • Tocilizumab (TCZ) demonstrates significant steroid-sparing effects in a real-life GCA cohort.
  • TCZ shows clinical efficacy and reduces GC-related toxicity and relapses in GCA patients.